TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder
April 19, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts Current Data Suggests Niclosamide Inhalation Powder is a Promising Antiviral Treatment to Combat...
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 24, 2022 16:26 ET
|
TFF Pharmaceuticals, Inc.
Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the...
TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures
March 17, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference
March 11, 2022 07:05 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022
March 09, 2022 16:05 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, March 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement
March 01, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Catalent to collaborate on the scalability and manufacturing for TFF Pharmaceuticals’ proprietary Thin Film Freezing technologyCollaboration focused on development of dry powder formulations of...
TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2
February 24, 2022 09:27 ET
|
TFF Pharmaceuticals, Inc.
Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of Effective Dose Expecting to Complete Phase 1...
TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19
January 27, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Complete Safety Data Anticipated by End of 1Q 2022 Safety Management Committee Has Recommended 12 mg as Phase 2 Dose Niclosamide is a Potent Inhibitor of SARS-CoV-2 with Activity Against Multiple...
TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients
December 21, 2021 08:00 ET
|
TFF Pharmaceuticals, Inc.
Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate...
TFF Pharmaceuticals Hosting Science Day on December 13, 2021
December 06, 2021 08:00 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...